PCA3 and pachyonychia congenita: While PCA3 urine test has shown promising for the diagnosis of PC patients and prediction of tumor volume, data from two recent independent studies that revealed a gradual reduction and eventual complete non-expression of PCA3 with ongoing hormone treatment [243,244] suggests that urinary PCA3 score are not reliable markers for assessing response to ADT in advanced prostate cancer.